Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 197-200

  Hertz, Daniel L ^a   Walko, Christine M ^a,b   Bridges, Arlene S ^c   Hull, J Heyward ^a   Herendeen, Jill ^a,d   Rollins, Kristan ^a,e   Watkins, Paul B ^a   Dees, E Claire ^b,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

Erythromycin breath test; In vivo probe; Paclitaxel; Rosiglitazone

Indexed keywords

CARBOPLATIN; ERYTHROMYCIN; PACLITAXEL; ROSIGLITAZONE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREATH ANALYSIS; CLINICAL ARTICLE; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; IN VIVO STUDY; LUNG CANCER; MALE; MELANOMA; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; PACLITAXEL; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; THIAZOLIDINEDIONES; TUBULIN MODULATORS;

EID: 84862127182     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04165.x     Document Type: Article

References (13)

1. Frye RF. Probing the world of cytochrome P450 enzymes. Mol Interv 2004; 4: 157-62.
2. Sparreboom A, Huizing MT, Boesen JJB, Nooijen WJ, Beijnen JH, Tellingen OV. Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 1995; 36: 299-304.
3. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8.
4. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32.
5. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84.
6. Freed MI, Allen A, Jorkasky DK, DiCicco RA. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol 1999; 55: 53-6.
7. Egorin M, Ramanathan R, Belani C, Zuhowski E, Rosen D, Parise R, Capozzoli M, Tauch J, Potter D, Trump D. Pharmacokinetics (PK) of, and limited sampling strategies (LSS) for 1-hour paclitaxel infusions [meeting abstract]. Proceedings of ASCO Volume 19; 2000 May 21-23; New Orleans, LA: ASCO; 2000 Abstract no 824.
8. Stinchcombe T, Socinski M, Walko C, O'Neil B, Collichio F, Ivanova A, Mu H, Hawkins M, Goldberg R, Lindley C, Claire Dees E. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60: 759-66.
9. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99: 44-51.
10. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31: 439-46.
11. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008; 84: 704-9.
12. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GDV, Ahmed MS. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone and metformin. Obstet Gynecol 2010; 202: 383.e1-383.e7.
13. Lehnert M, Emerson S, Dalton WS, de Giuli R, Salmon SE. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated taxol resistance. J Natl Cancer Inst Monogr 1993; 15: 63-7.